CT衰减值不能可靠区分骨活检患者的良性硬化性病变与成骨性转移瘤
该回顾性研究纳入1998年10月7日至2018年7月15日期间CT描述为硬化性病变并随后行活检的280例患者,其中恶性活检结果162例、良性118例。两位肌肉骨骼放射科医生测量病变最大和平均衰减值,采用既往发表的衰减阈值区分良恶性,结果显示良恶性病变间最大和平均衰减值均无显著差异(均P>.05),ROC分析未找到高性能替代阈值,ICC分别为0.946和0.918。
要点
- 良恶性硬化性病变的最大和平均CT衰减值均无显著差异(均P>.05)。
- 最大衰减阈值>1060 HU区分良恶性敏感度23.7%、特异度87.0%、准确率60.6%。
- 平均衰减阈值>885 HU区分良恶性敏感度19.5%、特异度90.7%、准确率60.7%。
诊断标准与关键数值
- 最大衰减阈值>1060 HU区分良性硬化性病变与成骨性转移瘤:敏感度23.7%、特异度87.0%、准确率60.6%。
- 平均衰减阈值>885 HU区分良性硬化性病变与成骨性转移瘤:敏感度19.5%、特异度90.7%、准确率60.7%。
- ROC曲线分析显示平均和最大衰减阈值的AUC分别为51.8%和54.6%。
- 两位读者最大衰减的ICC为0.946、平均衰减的ICC为0.918。
临床应用与阅片要点
- 作者结论指出,既往用于区分骨岛与成骨性转移瘤的CT衰减阈值不应更广泛地使用。
- 作者指出无法推导出更准确的替代阈值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. CT attenuation thresholds that accurately distinguish enostoses from untreated osteoblastic metastases have been published. In the Mayo Clinic practices, these thresholds have been applied more broadly to distinguish benign sclerotic bone lesions other than enostoses from osteoblastic metastases. OBJECTIVE. The purpose of this article is to determine if CT attenuation thresholds allow the distinguishing of benign sclerotic bone lesions from osteoblastic metastases in patients undergoing bone biopsy. METHODS. A retrospective search was conducted to identify sclerotic lesions described on CT between October 7, 1998, and July 15, 2018, that underwent subsequent biopsy. Two musculoskeletal radiologists recorded lesions' maximum and mean attenuation. Using previously published attenuation thresholds, sensitivity and specificity for differentiating benign sclerotic lesions from osteoblastic metastases were calculated. ROC curve analysis was performed to determine if more appropriate attenuation thresholds exist. Intraclass correlation coefficients (ICCs) were computed. RESULTS. A total of 280 patients met inclusion criteria. Of those, 162 had malignant biopsy results and 118 had benign biopsy results. Of the 162 malignant lesions, 81 had received prior treatment. Maximum and mean attenuation were not significantly different between benign and malignant lesions for either reader (all p > .05). For reader 1, to distinguish benign from malignant lesions, a maximum attenuation threshold of more than 1060 HU resulted in sensitivity of 23.7%, specificity of 87.0%, and accuracy of 60.6%. A mean attenuation threshold of greater than 885 HU resulted in sensitivity of 19.5%, specificity of 90.7%, and accuracy 60.7%. ROC curve analysis showed AUCs for mean and maximum attenuation thresholds of 51.8% and 54.6%, respectively. Subgroup analyses of benign versus malignant and treated versus untreated lesions had similar results. Similar findings were obtained for reader 2. The two readers' ICC was 0.946 for maximum attenuation and 0.918 for mean attenuation. CONCLUSION. Published attenuation thresholds for distinguishing enostoses from osteoblastic metastases had slightly decreased specificity and markedly decreased sensitivity when applied to the differentiation of benign sclerotic lesions from osteoblastic metastases in our sample of biopsy-proven lesions. ROC analysis showed no high-performing attenuation threshold alternative. CLINICAL IMPACT. Published CT attenuation thresholds intended for distinguishing enostoses from osteoblastic metastases should not be used more broadly. More accurate alternative thresholds could not be derived.
引用
- Azar A, Garner HW, Rhodes NG, et al. CT Attenuation Values Do Not Reliably Distinguish Benign Sclerotic Lesions From Osteoblastic Metastases in Patients Undergoing Bone Biopsy. AJR Am J Roentgenol. 2021. PMID: 32755207. doi:10.2214/AJR.20.24029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。